| Name | Title | Contact Details |
|---|
Its never easy to admit that you or someone you care about is addicted to alcohol or drugs. But once you recognize the problem, the road to recovery appears at your feet. The first step down that road is to find professional help.
Tenex Madication is a Incline Village, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AutoCruitment is a metrics-driven ecosystem of patient recruitment and engagement solutions, digitizing and revolutionizing the end-to-end patient and client experience. Our multifaceted approach utilizes sophisticated algorithms, advanced automation, and over 1,500 direct-to-patient online channels to find, screen, and automatically refer highly qualified patients with a greater chance of randomization success. The results are higher enrollment and greater patient engagement, accelerating timelines and exceeding milestones at every phase of clinical research. The AutoCruitment Difference: •Targeted: The AutoCruitment platform`s proprietary algorithms and innovative approach help precisely target your ideal patient population, reaching over 247 million patients to date •Experienced: AutoCruitment has completed over 578 studies and has a continuously learning and growing database of over 10 million patients •Technology-Enabled: The AutoCruitment platform utilizes advanced online screeners to simultaneously screen for multiple studies and provide customized cohort volumes based on your project`s needs •Volume- and Quality-Focused: The far-reaching power of the AutoCruitment platform and our direct-to-patient methodology excels at attracting and retaining optimal volumes of highly qualified patients •Transparent: The AutoCruitment portal and its robust reporting capabilities enable complete and real-time transparency from the very beginning •Metrics-Driven: Our patient recruitment scientists work in complete collaboration with your study teams and research sites to optimize the program and increase randomization by an average of 97% per month AutoCruitment delivers something different. Our comprehensive ecosystem of scalable solutions offers a 3-day startup time and swiftly removes the recruitment barrier for biotech innovations and pharmaceutical research, shortening timelines and trimming budgets for a quicker, smoother path to market.
Beckman Coulter Inc. is a Danaher Corporation company that develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.